Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in AQP4-IgG Positive NMOSD Patients With Inadequate Response to Rituximab
ChiCTR2600123342Phase 4Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telitacicept in neuromyelitis optica spectrum disorder (NMOSD), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: 48-week recurrence-free rate and Diffusion Tensor Imaging (DTI) parameters (FA, MD). Started Apr 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
neuromyelitis optica spectrum disorder (NMOSD)
Beyond the preview
Go deeper on ChiCTR2600123342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123342.